BioLineRx Ltd. (BLRX) Given Average Recommendation of “Buy” by Brokerages
BioLineRx Ltd. (NASDAQ:BLRX) has been assigned a consensus rating of “Buy” from the seven brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $2.88.
A number of equities research analysts recently weighed in on BLRX shares. Maxim Group set a $3.00 price objective on shares of BioLineRx and gave the company a “buy” rating in a report on Monday, July 10th. ValuEngine upgraded shares of BioLineRx from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Zacks Investment Research upgraded shares of BioLineRx from a “sell” rating to a “hold” rating in a report on Wednesday, July 26th. Roth Capital started coverage on shares of BioLineRx in a report on Thursday, August 3rd. They set a “buy” rating and a $3.00 price objective for the company. Finally, Oppenheimer Holdings, Inc. started coverage on shares of BioLineRx in a report on Friday, August 4th. They set an “outperform” rating and a $3.00 price objective for the company.
Large investors have recently bought and sold shares of the company. KCG Holdings Inc. raised its holdings in shares of BioLineRx by 715.9% in the 1st quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 153,687 shares in the last quarter. Citadel Advisors LLC raised its stake in shares of BioLineRx by 443.4% during the 1st quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 86,481 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of BioLineRx during the 1st quarter worth approximately $126,000. Institutional investors and hedge funds own 32.27% of the company’s stock.
TRADEMARK VIOLATION WARNING: “BioLineRx Ltd. (BLRX) Given Average Recommendation of “Buy” by Brokerages” was first posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/25/biolinerx-ltd-blrx-given-average-recommendation-of-buy-by-brokerages.html.
BioLineRx (NASDAQ:BLRX) traded down 0.92% during trading on Wednesday, reaching $1.08. 303,358 shares of the company were exchanged. BioLineRx has a 1-year low of $0.80 and a 1-year high of $1.38. The company’s 50-day moving average price is $1.13 and its 200-day moving average price is $0.98. The stock’s market capitalization is $103.27 million.
BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05). On average, equities analysts forecast that BioLineRx will post ($0.24) EPS for the current year.
BioLineRx Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.